Remimazolam Versus Propofol in Adult Cardiac Surgery
Remimazolam keeps showing up in cardiac anesthesia conversations, mostly for steadier hemodynamics than propofol. An October 8, 2026 systematic review and meta-analysis in the Journal of Cardiothoracic and Vascular Anesthesia pooled randomized trials of remimazolam-based versus propofol-based induction and maintenance in adults undergoing cardiac surgery.
The study
Fourteen reports of randomized trials, including three dissertations, contributed 1,773 participants to the primary synthesis. All of those trials were conducted in China. No key pooled result rested only on low risk-of-bias evidence. A small terminated European registry-results trial (23 treated patients) was added as sensitivity material. Major postoperative morbidity and mortality data were too sparse to pool.
Remimazolam was associated with fewer trial-defined intraoperative hypotension events (OR 0.31, 95% CI 0.20 to 0.47) and fewer bradycardia events (OR 0.20, 95% CI 0.12 to 0.34). Mechanical ventilation duration was shorter (mean difference about 1.8 hours shorter). Hospital length of stay did not clearly differ. Certainty of evidence for the hemodynamic and ventilation findings was rated very low.
Why it matters
The direction of the hemodynamic signal matches what many of us have seen at the bedside: remimazolam often looks gentler than propofol on blood pressure and heart rate around induction. The catch is the certainty rating. Geography, bias risk, and sparse hard-outcome data all limit how far you can push these pooled odds ratios into a practice change. The authors are clear that the evidence does not establish better major morbidity or mortality.
What it means for practice here
I do not treat this meta-analysis as a mandate to switch every cardiac case to remimazolam. It is useful context when I am choosing induction and maintenance for a patient who looks fragile on induction, and when I am weighing how much of the "cleaner hemodynamics" story is real versus under-tested. Propofol remains familiar, titratable, and well supported. Remimazolam may earn a seat in selected cardiac cases, but I want multicenter confirmation and better morbidity endpoints before I call it a default.
For now, I will keep watching for larger, more geographically diverse trials. The hypotension and bradycardia associations are interesting. The certainty grade is the part I will not ignore.
Source
- Yao YT, Huang S, Wang HB, et al. Remimazolam versus propofol for anesthesia induction and maintenance in adult cardiac surgical patients: a PRISMA-compliant systematic review and meta-analysis. Journal of Cardiothoracic and Vascular Anesthesia. Published online October 8, 2026. doi:10.1053/j.jvca.2026.10.008. Article (JCVA)
This post is clinician commentary for educational discussion. It is not medical advice for any reader's personal care. Anesthesia and perioperative decisions should be made with the treating clinician based on the individual patient's circumstances.